Literature DB >> 32298120

Discovery and Structure-Activity Relationship Study of (Z)-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.

Theresa D Manz1,2,3, Sindhu Carmen Sivakumaren1,2, Fleur M Ferguson1,2, Tinghu Zhang1,2, Adam Yasgar4, Hyuk-Soo Seo1,2, Scott B Ficarro5,6,7, Joseph D Card5,6,7, Hyeseok Shim8, Chandrasekhar V Miduturu1,2, Anton Simeonov4, Min Shen4, Jarrod A Marto5,6,7, Sirano Dhe-Paganon1,2, Matthew D Hall4, Lewis C Cantley8, Nathanael S Gray1,2.   

Abstract

Due to their role in many important signaling pathways, phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are attractive targets for the development of experimental therapeutics for cancer, metabolic, and immunological disorders. Recent efforts to develop small molecule inhibitors for these lipid kinases resulted in compounds with low- to sub-micromolar potencies. Here, we report the identification of CVM-05-002 using a high-throughput screen of PI5P4Kα against our in-house kinase inhibitor library. CVM-05-002 is a potent and selective inhibitor of PI5P4Ks, and a 1.7 Å X-ray structure reveals its binding interactions in the ATP-binding pocket. Further investigation of the structure-activity relationship led to the development of compound 13, replacing the rhodanine-like moiety present in CVM-05-002 with an indole, a potent pan-PI5P4K inhibitor with excellent kinome-wide selectivity. Finally, we employed isothermal cellular thermal shift assays (CETSAs) to demonstrate the effective cellular target engagement of PI5P4Kα and -β by the inhibitors in HEK 293T cells.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32298120      PMCID: PMC7292230          DOI: 10.1021/acs.jmedchem.0c00227

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  41 in total

Review 1.  The logic of TGFbeta signaling.

Authors:  Joan Massagué; Roger R Gomis
Journal:  FEBS Lett       Date:  2006-04-21       Impact factor: 4.124

2.  Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo.

Authors:  Xiaolei Ye; Wu Zhou; Yongqi Li; Yihua Sun; Yihua Zhang; Hui Ji; Yisheng Lai
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-30       Impact factor: 3.333

3.  Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.

Authors:  Sindhu Carmen Sivakumaren; Hyeseok Shim; Tinghu Zhang; Fleur M Ferguson; Mark R Lundquist; Christopher M Browne; Hyuk-Soo Seo; Marcia N Paddock; Theresa D Manz; Baishan Jiang; Ming-Feng Hao; Pranav Krishnan; Diana G Wang; T Jonathan Yang; Nicholas P Kwiatkowski; Scott B Ficarro; James M Cunningham; Jarrod A Marto; Sirano Dhe-Paganon; Lewis C Cantley; Nathanael S Gray
Journal:  Cell Chem Biol       Date:  2020-03-03       Impact factor: 8.116

4.  PIP4K2A regulates intracellular cholesterol transport through modulating PI(4,5)P2 homeostasis.

Authors:  Ao Hu; Xue-Tong Zhao; Heng Tu; Ting Xiao; Ting Fu; Yan Wang; Yong Liu; Xiong-Jie Shi; Jie Luo; Bao-Liang Song
Journal:  J Lipid Res       Date:  2018-01-20       Impact factor: 5.922

Review 5.  PtdIns5P and Pin1 in oxidative stress signaling.

Authors:  Willem-Jan Keune; David R Jones; Nullin Divecha
Journal:  Adv Biol Regul       Date:  2013-03-13

Review 6.  Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2015-10-31       Impact factor: 7.658

7.  Overexpression of the amplified Pip4k2beta gene from 17q11-12 in breast cancer cells confers proliferation advantage.

Authors:  Shiuh-Wen Luoh; Natarajan Venkatesan; Reshimi Tripathi
Journal:  Oncogene       Date:  2004-02-19       Impact factor: 9.867

8.  Inhibition of PIP4Kγ ameliorates the pathological effects of mutant huntingtin protein.

Authors:  Lois S Weisman; Juan Botas; Ismael Al-Ramahi; Sai Srinivas Panapakkam Giridharan; Yu-Chi Chen; Samarjit Patnaik; Nathaniel Safren; Junya Hasegawa; Maria de Haro; Amanda K Wagner Gee; Steven A Titus; Hyunkyung Jeong; Jonathan Clarke; Dimitri Krainc; Wei Zheng; Robin F Irvine; Sami Barmada; Marc Ferrer; Noel Southall; Juan Jose Marugan
Journal:  Elife       Date:  2017-12-26       Impact factor: 8.140

9.  The function of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) explored using a specific inhibitor that targets the PI5P-binding site.

Authors:  Jonathan H Clarke; Maria-Luisa Giudici; John E Burke; Roger L Williams; David J Maloney; Juan Marugan; Robin F Irvine
Journal:  Biochem J       Date:  2015-03-01       Impact factor: 3.857

Review 10.  Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?

Authors:  Zheng Zhao; Hong Wu; Li Wang; Yi Liu; Stefan Knapp; Qingsong Liu; Nathanael S Gray
Journal:  ACS Chem Biol       Date:  2014-04-29       Impact factor: 5.100

View more
  5 in total

Review 1.  Expanding role of PI5P4Ks in cancer: A promising druggable target.

Authors:  Gurpreet K Arora; Lavinia Palamiuc; Brooke M Emerling
Journal:  FEBS Lett       Date:  2021-12-07       Impact factor: 3.864

2.  Identification of Small-Molecule Inhibitors of Human Inositol Hexakisphosphate Kinases by High-Throughput Screening.

Authors:  Gangling Liao; Wenjuan Ye; Tyler Heitmann; Glen Ernst; Michael DePasquale; Laiyi Xu; Michael Wormald; Xin Hu; Marc Ferrer; Robert K Harmel; Dorothea Fiedler; James Barrow; Huijun Wei
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-03

3.  Pharmacological inhibition of PI5P4Kα/β disrupts cell energy metabolism and selectively kills p53-null tumor cells.

Authors:  Song Chen; Caroline Chandra Tjin; Xiang Gao; Yi Xue; Haoyan Jiao; Ruilin Zhang; Mengnan Wu; Zunyu He; Jonathan Ellman; Ya Ha
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-25       Impact factor: 11.205

4.  Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode.

Authors:  Helen K Boffey; Timothy P C Rooney; Henriette M G Willems; Simon Edwards; Christopher Green; Tina Howard; Derek Ogg; Tamara Romero; Duncan E Scott; David Winpenny; James Duce; John Skidmore; Jonathan H Clarke; Stephen P Andrews
Journal:  J Med Chem       Date:  2022-02-11       Impact factor: 8.039

5.  PIP4Ks impact on PI3K, FOXP3, and UHRF1 signaling and modulate human regulatory T cell proliferation and immunosuppressive activity.

Authors:  Alessandro Poli; Shidqiyyah Abdul-Hamid; Antonio Enrico Zaurito; Francesca Campagnoli; Valeria Bevilacqua; Bhavwanti Sheth; Roberta Fiume; Massimiliano Pagani; Sergio Abrignani; Nullin Divecha
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-03       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.